Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

441
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
441
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

234
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Socioeconomic status and cognitive function in older adults: the mediating roles of social activity and loneliness in three aging cohorts.

BMC public health·2026
Same author

Disruption of dynactin complex function in intellectual disability.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Resveratrol suppresses GATA4/Sortilin pathway to attenuate vascular smooth muscle cell senescence-associated secretory phenotype and vascular aging-related atherosclerosis.

Cellular signalling·2026
Same author

Machine Learning-Based Accurate Full-Sib Family Assignment in Sturgeon Using Whole-Genome Sequencing Data.

International journal of molecular sciences·2026
Same author

Investigating the double-edged sword effect of GenAI use on international students' school adjustment.

Frontiers in psychology·2026
Same author

Repositioning of exercise treadmill testing in contemporary chest pain management.

The international journal of cardiovascular imaging·2026

Related Experiment Video

Updated: Oct 13, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.6K

Siponimod for multiple sclerosis.

Liujiao Cao1,2, Meixuan Li3, Liang Yao4

  • 1West China School of Nursing/West China Hospital, Sichuan University, Chengdu, China.

The Cochrane Database of Systematic Reviews
|November 16, 2021
PubMed
Summary
This summary is machine-generated.

Siponimod may reduce disability progression and relapse rates in multiple sclerosis (MS) patients, but evidence quality is low. Further research is needed to confirm siponimod

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Related Experiment Videos

Last Updated: Oct 13, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic, immune-mediated central nervous system disease with unpredictable progression.
  • Current therapies aim to manage exacerbations and slow disability.
  • Siponimod, a selective sphingosine-1-phosphate (S1P) receptor modulator, is an oral treatment for relapsing forms of MS.

Purpose of the Study:

  • To assess the benefits and adverse effects of siponimod in MS patients.
  • To compare siponimod (as monotherapy or combination therapy) against placebo or active comparators.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) including parallel controlled clinical trials.
  • Searched Cochrane MS and Rare Diseases of the CNS Trials Register, MEDLINE, Embase, ClinicalTrials.gov, and WHO ICTRP.
  • Primary outcomes included disability worsening, relapse, and adverse events; secondary outcomes included annualized relapse rate and MRI lesion changes.

Main Results:

  • Two RCTs (1948 participants) compared siponimod to placebo, with a high risk of bias.
  • Siponimod may reduce disability progression (low-certainty evidence) and annualized relapse rate (low-certainty evidence).
  • Evidence for reducing new relapses is very low-certainty; no significant difference in adverse events was observed (low-certainty evidence).

Conclusions:

  • Uncertainty exists regarding siponimod's benefits for MS due to low to very low certainty of evidence.
  • Study limitations, including short follow-up (<24 months) and high risk of bias, necessitate further research.
  • More robust studies with longer follow-up and comparisons against other therapies are needed.